You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

CLINICAL TRIALS PROFILE FOR AKST4290

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for AKST4290

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT03558061 ↗	Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration	Completed	Alkahest, Inc.	Phase 2	This study will evaluate the therapeutic effects and safety of 800 mg ALK4290 administered daily over a 6-week dosing period in newly diagnosed patients with wet age-related macular degeneration (wAMD).
NCT03558074 ↗	Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration	Completed	Alkahest, Inc.	Phase 2	This study will evaluate the therapeutic effects and safety of 800 mg ALK4290 administered daily over a 6-week dosing period in subjects with refractory wet age-related macular degeneration (wAMD).
NCT04331730 ↗	A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD	Completed	Alkahest, Inc.	Phase 2	This study will evaluate the efficacy and safety of AKST4290 in combination with aflibercept injections in subjects with newly diagnosed neovascular age-related macular degeneration (nAMD).
NCT04369430 ↗	Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment	Completed	Alkahest, Inc.	Phase 2	This study will evaluate the efficacy and safety of AKST4290 in subjects with Parkinson's Disease who are currently on stable dopaminergic treatment.
NCT04499235 ↗	A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid	Completed	Alkahest, Inc.	Phase 2	This study will evaluate the therapeutic effect and safety of adjunctive AKST4290 in subjects with bullous pemphigoid (BP).
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for AKST4290

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Wet Age-related Macular Degeneration	2
Diabetic Retinopathy	1
Neovascular Age-related Macular Degeneration	1
Parkinson Disease	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Macular Degeneration	3
Wet Macular Degeneration	1
Retinal Diseases	1
Diabetic Retinopathy	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for AKST4290

Trials by Country

Map
Table

Trials by Country
Location	Trials
United States	13
Hungary	4
Germany	3
Poland	2
Slovakia	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State
Location	Trials
Florida	2
California	2
Utah	1
Texas	1
South Carolina	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for AKST4290

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 2	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	5
Recruiting	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for AKST4290

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
Alkahest, Inc.	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
Industry	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.